Radiopharm Theranostics Signs Supply Deal With Siemens Healthineers For RAD101

Radiopharm Theranostics (RADX) signed a supply agreement with Siemens Healthineers for RAD101, a novel FASN-targeting imaging small molecule to diagnose suspected recurrent brain metastases. The deal with a major imaging partner should accelerate clinical deployment and commercial readiness but likely has limited near-term revenue impact until commercial terms or volumes are disclosed. Monitor upcoming clinical/regulatory milestones and any financial terms for potential re-rating.

Analysis

Radiopharm Theranostics (RADX) signed a supply agreement with Siemens Healthineers for RAD101, a novel FASN-targeting imaging small molecule to diagnose suspected recurrent brain metastases. The deal with a major imaging partner should accelerate clinical deployment and commercial readiness but likely has limited near-term revenue impact until commercial terms or volumes are disclosed. Monitor upcoming clinical/regulatory milestones and any financial terms for potential re-rating.